Briefing
No Smoking Day 2022: Reflecting on OHE Projections from 1994
9 March 2022
Since 1984, the UK’s second Wednesday of each March is NO SMOKING DAY (NSD). The NSD aims to encourage smokers who want to quit. In 2022,…
Key Learnings From COVID-19: The Importance of Portfolio Management and How to Procure, Pay For, Distribute, and Use Vaccines During a Pandemic
21 April 2021
In this blog, we reflect on some of the key learnings from the recent pull and push strategies to develop COVID-19 vaccines in the UK, the…
OHE Launches Discussion Paper and Consultation Exercise on Indication-based Pricing
10 May 2019
Increasingly, scientific advances are delivering new medicines that deliver improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as…
Quality of Life and Rare Disease: Lessons from Spinal Muscular Atrophy
2 April 2019
The measurement of quality of life in the context of spinal muscular atrophy (SMA) is challenging. This is because the disease is experienced by children and…
Approaches, Challenges and Successful Stories of Multi-indication Pricing in Europe
28 November 2018
Multi-Indication Pricing: Practical Solutions and Steps to Move Forward. A summary of an HTAi panel session.
Private Provision of Publicly Funded Health Care: The Economics of Ownership
10 September 2018
A new OHE Briefing by Martin Chalkley (University of York) and Jon Sussex (RAND Europe) provides a view of the NHS ownership debate through the lens…
Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help? A Summary of a Symposium held at HTAi Rome 2017
31 October 2017
OHE has just published a new briefing entitled ‘Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?’
Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions
30 May 2017
Without new antibiotics, more patients will die from previously treatable infections. A key issue is how the value of antibiotics can be appropriately assessed by payers…
Incentives for New Drugs and Vaccines to Tackle Anti-Microbial Resistance
16 May 2017
Resistance to antibiotics is growing. Additional R&D is required. Both Transferable Intellectual Property Rights and Market Entry Rewards should be explored for use in Europe as…